Company Intelligence
Kelun-Biotech
科伦博泰
No Known BCC Exposure
Kelun-Biotech is a drug innovator, not a CDMO/CRO. No BIOSECURE exposure. Licensing Kelun ADC assets does not create federal contracting risk.
Overview
Kelun-Biotech (科伦博泰) is one of China's most prolific ADC (antibody-drug conjugate) development platforms. Spun out from Kelun Pharmaceutical Group, the company has built a proprietary linker-payload technology platform that has attracted major Western partnerships — most notably a $9.4B multi-target collaboration with Merck. Kelun-Biotech represents the depth of Chinese ADC innovation beyond the headline deals.
Key Facts
- Merck partnership valued at $9.4B+ across multiple ADC candidates — one of the largest China ADC deals
- Proprietary OptiDC linker-payload technology platform
- Multiple ADC candidates in clinical development across oncology indications
- Parent company Kelun Pharmaceutical (SZ: 002422) provides manufacturing infrastructure
Key Deals
| Partner | Date | Value | Asset |
|---|---|---|---|
| Merck | 2022-ongoing | $9.4B+ | Multi-target ADC collaboration (7 targets) |
Corporate Structure
Hong Kong-listed subsidiary of Kelun Pharmaceutical Group (科伦药业, SZ: 002422). Kelun Pharmaceutical retains majority control. Operating entity: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.